Litcius/Paper detail

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐A

Keith W. Pratz, Courtney D. DiNardo, Dominik Selleslag, Junmin Li, Kazuhito Yamamoto, Marina Konopleva, Don A. Stevens, Hagop M. Kantarjian, Fabı́ola Traina, Adriano Venditti, Jiří Mayer, Melissa Montez, Huan Jin, Yinghui Duan, Deanna J. Brackman, Jiuhong Zha, Jalaja Potluri, Michael E. Werner, Brian A. Jonas

2022American Journal of Hematology30 citationsDOI

Abstract

Postremission cytopenia management in patients with

Topics & Concepts

CytopeniaAzacitidineMyeloid leukemiaMedicineInternal medicineVenetoclaxOncologyLeukemiaBiologyBone marrowBiochemistryChronic lymphocytic leukemiaGeneDNA methylationGene expressionAcute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationBlood disorders and treatments
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐A | Litcius